drugset / Trial / NCT06853184

Study Evaluating the Efficacy and Safety of Artesunate

NCT06853184

Phase 2 Recruiting 90 enrolled Amivas Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a randomized, open-label, active comparator-controlled, dose-ranging trial of the efficacy and safety of IV artesunate in combination with IV GCV or oral VGCV and SOC treatment compared to GCV or VGCV monotherapy and SOC treatment in SOT recipients with clinically significant CMV infection.

Timeline

Start
2025-08-01
Primary completion
2028-05-31
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Artesunate Small molecule 2.4 mg/kg Intravenous
Subject Artesunate Small molecule 4.8 mg/kg Intravenous
Comparator Ganciclovir Small molecule
Comparator Valganciclovir Small molecule